AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04205279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Surefooted training
Description: During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
Study NCT02275897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow Speed of spinal injection
Description: Speed of injection over 60 seconds
Study NCT02275897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast Speed of spinal injection
Description: Speed of injection over 15 seconds
Study NCT00718042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay
Description: Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
Study NCT00718042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay
Description: Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
Study NCT03135223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-created intervention to promote physical activity
Description: A working group of girls and researcher co-created a school-specific intervention to promote physical activity
Study NCT00304070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04556877 — intervention group
Intervention type: PROCEDURE
Intervention: Intraabdominal pressure and optic nerve diameters
Description: Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
Study NCT00304070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo surgery
Study NCT00304070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00304070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00304070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously
Study NCT00304070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Given orally
Study NCT00304070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given subcutaneously
Study NCT01049880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with escalating ascorbic acid
Description: Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL.
Study NCT01542112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSactive model
Description: The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention.
Study NCT01542112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Patients in this arm receive the usual routine in the department.
Study NCT00575588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: open-label metformin
Study NCT00575588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
Study NCT00575588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Saxagliptin 5 mg tablets
Study NCT05212636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
Study NCT03525834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
Study NCT01375296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: China-made SES (Firebird 2 and Excel)
Description: patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
Study NCT01375296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: routine medicine
Description: patients with coronary 50-70% narrowing treated with routine medicine
Study NCT03367533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous ketamine
Study NCT03367533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Intravenous ketamine
Study NCT03367533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral perampanel (6 mg)
Study NCT02618772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
Study NCT02618772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
Study NCT03367533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT01913444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Antithrombin
Study NCT02412345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Study NCT04461626 — intervention group
Intervention type: DEVICE
Intervention: Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)
Study NCT02691858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
Study NCT02691858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
Study NCT01202838 — intervention group
Intervention type: DEVICE
Intervention: Composite Implant
Description: Subjects receiving composite implants
Study NCT03206021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Azacytidine
Description: Dose escalation of carboplatin combined with 5'azacytidine
Study NCT03054909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803 Subcutaneous
Description: Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
Study NCT03054909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803 Intraperitoneal
Description: Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
Study NCT01412424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide capsules
Description: Octreotide was provided in hard gelatin capsules.
Study NCT04614428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RESILIENCE Program
Description: In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective.
Study NCT00962429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipoic acid
Description: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Study NCT00962429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lipoic acid
Description: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Study NCT05634265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vijana-SMART
Description: The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
Study NCT01970332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization Surgery
Study NCT01970332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Study NCT03327480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthosis
Description: Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
Study NCT02412345 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shockwave therapy - sham treatment
Description: A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
Study NCT02412345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil
Description: Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
Study NCT04574622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
Study NCT03860389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
Study NCT02897843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
Study NCT02897843 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study NCT01405157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: constituted powder for oral suspension 4 mg/mL single dose at 16 mg
Study NCT01405157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablets 16 mg single dose
Study NCT03606161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03606161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Undergo nrTMS
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Monthly Weight
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.
Study NCT06701383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Pulmonary vein isolation using cryoablation
Study NCT06701383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Pulmonary vein isolation using cryoablation
Study NCT06701162 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasoud-guided TAP block
Description: the ultrasound probe was placed at the mid-axillary line, and the needle was inserted into the space between the internal oblique and transverse muscles, splitting the inter-muscular fascia after injection of local anesthetic.
Study NCT06701162 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound-guided Ilio-inguinal Ilio-Hypogatric block
Description: the ultrasound probe was positioned transversely on the abdominal wall at the contact point of the anterosuperior iliac spine. The needle was inserted into the space between the internal oblique and transverse muscles, causing separation of the intermuscular fascia layers upon injection of the anesthetic mixture
Study NCT06701448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: robotic bronchosopy
Description: robotic bronchoscopy
Study NCT06701448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electromagnetic Navigation Bronchoscopy
Description: Electromagnetic Navigation Bronchoscopy
Study NCT06701448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fluoroscopy bronchoscopy
Description: Fluoroscopy bronchoscopy
Study NCT06700941 — intervention group
Intervention type: BIOLOGICAL
Intervention: HPV vaccine
Description: The intervention of interest in this observational study is the HPV vaccine, which was introduced as part of Colombia's national immunization program in 2012. The vaccine is administered to girls between the ages of 9 and 17 to prevent cervical cancer, preneoplastic cervical lesions, and genital warts caused by HPV infection. The vaccine schedule typically includes two doses given over six months.~This study does not involve administering the vaccine as part of the research. Instead, it retrospectively analyzes the healthcare records of individuals who received the vaccine as part of routine care and compares outcomes with those who were not vaccinated.
Study NCT03086642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Overall Weight + Exercise
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Overall Weight
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Overall Weight
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Overall Weight + Exercise
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Monthly Weight + Exercise
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Monthly Weight
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.
Study NCT03834194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Monthly Weight + Exercise
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.
Study NCT02515019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index Monitoring
Description: In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
Study NCT01590914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
Study NCT01590914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasted Condition
Description: Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
Study NCT03610490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Description: Given IV
Study NCT03610490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03610490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03610490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given IV
Study NCT03610490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02412345 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil
Description: Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
Study NCT01430416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071